Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE

Launched by UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF · Mar 14, 2022

Keywords

ClinConnect Summary

This clinical trial, called the Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute Stroke, is studying whether starting treatment for atrial fibrillation (a heart rhythm problem) soon after an ischemic stroke (a type of stroke caused by a blood clot) can help prevent further heart-related issues. The trial aims to compare this early treatment approach with the usual care patients receive after a stroke.

To participate in this trial, individuals need to have had an ischemic stroke within the last four weeks and must be able to start the treatment within that time frame. They should also have been diagnosed with atrial fibrillation within the past year. Unfortunately, people with certain serious health conditions, like advanced cancer or those who have previously undergone specific heart procedures, won't be eligible. Participants can expect to receive close monitoring and care related to their heart rhythm and overall health throughout the study. This trial is not yet recruiting participants, but it will include both men and women aged 65-74.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Acute ischemic stroke in the previous four weeks, diagnosed by imaging (CT or MRI) or clinical diagnosis
• • Possibility to start the trial treatment within 4 weeks after stroke, and as soon as clinically justifiable
• • AF first detected ≤1 year prior to randomization
• • Informed consent
• Exclusion Criteria:
• • End-stage cancer or life-expectancy \< 12 months due to other advanced co-morbid illness
• • Prior AF ablation or surgical therapy of AF
• • Patients not suitable for rhythm control of AF due to cardiac conditions